| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6923983 | ELI LILLY AND CO | Transdermal delivery of hormones |
Feb, 2017
(7 years ago) | |
| US8071075 | ELI LILLY AND CO | Dermal penetration enhancers and drug delivery systems involving the same |
Feb, 2017
(7 years ago) | |
| US6299900 | ELI LILLY AND CO | Dermal penetration enhancers and drug delivery systems involving same |
Feb, 2017
(7 years ago) | |
| US6818226 | ELI LILLY AND CO | Dermal penetration enhancers and drug delivery systems involving same |
Feb, 2017
(7 years ago) | |
| US8784878 | ELI LILLY AND CO | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Jul, 2023
(9 months ago) | |
| US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(3 years from now) | |
Axiron is owned by Eli Lilly And Co.
Axiron contains Testosterone.
Axiron has a total of 11 drug patents out of which 5 drug patents have expired.
Expired drug patents of Axiron are:
- US6923983
- US8071075
- US6299900
- US6818226
- US8784878
Axiron was authorised for market use on 23 November, 2010.
Axiron is available in solution, metered;transdermal dosage forms.
Axiron can be used as testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone, a method of increasing the testosterone blood level of a person in need thereof, a method of increasing the testosterone blood level of an adult male subject in need thereof, a method of transdermal administration of a physiologically active agent to a subject., a method of transdermally delivering testosterone.
The generics of Axiron are possible to be released after 27 September, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; A method of transdermally delivering testosterone; A method of increasing t...
Dosage: SOLUTION, METERED;TRANSDERMAL
AXIRON family patents
